Company Bioheart, Inc. Other OTC
Equities
US09062F2011
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
2023 | U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2023 | U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt | CI |
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Autologous Cell Therapies
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -59.13% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -59.13% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Miguel Tomás
CEO | Chief Executive Officer | 58 | 02-12-31 |
Mark Borman
CHM | Chairman | 69 | 09-04-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Greg Knutson
BRD | Director/Board Member | 72 | 17-03-04 |
Director/Board Member | 100 | 03-05-31 | |
Mark Borman
CHM | Chairman | 69 | 09-04-30 |
Miguel Tomás
CEO | Chief Executive Officer | 58 | 02-12-31 |
Sheldon Anderson
BRD | Director/Board Member | 73 | 13-08-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 641,507,317 | 571,247,298 ( 89.05 %) | 0 | 89.05 % |
Company contact information
U.S. Stem Cell, Inc.
1560 Sawgrass Corporate Parkway 4th floor
33323-6217, Sunrise
+954 835 1500
http://www.us-stemcell.com![address Bioheart, Inc.](https://cdn.zonebourse.com/static/address/11095482.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+21.22% | 127B | |
+23.68% | 116B | |
+25.15% | 27.69B | |
-19.42% | 19.62B | |
-16.57% | 16.26B | |
-16.22% | 15.49B | |
+11.70% | 14.81B | |
-46.65% | 14.39B | |
+57.89% | 14.11B |
- Stock Market
- Equities
- USRM Stock
- Stock
- Company Bioheart, Inc.